GHK | Jotup

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on:

Wednesday, August 23, 2023

Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Multimedia, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points:

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on:

Wednesday, August 23, 2023

Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points:

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

GHK Capital Partners LP Completes the Sale of Hasa

Retrieved on:

Friday, January 13, 2023

Sale, GHK, Acquisition, Wardwell, Financial services, Bank

GREENWICH, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- GHK Capital Partners LP ("GHK"), a Greenwich, Connecticut based middle-market private equity firm, announced today that it recently completed the sale of Hasa, Inc. ("Hasa").

Key Points:

GREENWICH, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- GHK Capital Partners LP ("GHK"), a Greenwich, Connecticut based middle-market private equity firm, announced today that it recently completed the sale of Hasa, Inc. ("Hasa").
Hasa, based in Saugus, CA, manufactures and distributes water treatment products used to sanitize and maintain recreational, commercial, and industrial water systems, primarily in the western and southwestern U.S. Hasa was acquired by GHK in July 2020, and was the first platform investment made by GHK Fund I.
Terms of the acquisition were not disclosed.
Hasa was advised by KeyBanc Capital Markets Inc. and represented by Davis Polk & Wardwell LLP.

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on:

Monday, July 4, 2022

Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Pharmacy and Poisons Board, Pharmacy, Influenza A virus subtype H1N1, School, Admission, CEO, RNA transfection, Adult, Research, GHK, Trial of the century, Polio, Li Ka Shing Faculty of Medicine, Wong Chuk Hang, Infection, COVID-19, Immunization, Â, Sinovac Biotech, Department of Medicine – University of Pamplona, HKU, Omicron, School of Clinical Medicine, University of Cambridge, LKS, Viral hepatitis, Asia-Pacific, Campus Biotech, IHH Healthcare, Poison, Clinical trial, NWS Holdings, University, IRB, Virus, Pyaar Tune Kya Kiya (TV series), Animal, Vaccine, Chickenpox, Safety, University of Hong Kong, Vaccination, EV71, Immunity, Faculty, Mumps, Bed, Multimedia, International business, Volunteering, Pharmaceutical industry, Medicine, Gleneagles Hospital

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points:

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

GHK Capital Partners LP Completes Acquisition of Auveco

Retrieved on:

Monday, May 9, 2022

Maintenance, Ash Koley, GLOBE, GHK, Company, Fifth Third Bank, Partnership, Industry, Lincoln International, Wardwell, Growth, Acquisition, Video game

GREENWICH, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- GHK Capital Partners LP ("GHK"), a leading middle-market private equity firm, announced today that it completed the acquisition of Auveco (the "Company"), based in Cold Spring, KY.

Key Points:

GREENWICH, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- GHK Capital Partners LP ("GHK"), a leading middle-market private equity firm, announced today that it completed the acquisition of Auveco (the "Company"), based in Cold Spring, KY.
GHK's acquisition of Auveco will enable the Company to pursue future organic and inorganic growth initiatives as it continues to expand and evolve its product portfolio, supplier base, and customer-focused sales strategy.
GHK is a leading middle-market private equity firm focused on making control investments in industrial companies across North America.
GHK targets established businesses with strong free cash flow margins and multiple avenues for organic growth and operational improvement.

Hong Kong to be gateway for CMR Surgical in APAC region

Retrieved on:

Thursday, April 28, 2022

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at CUHK Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).

Key Points:

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at CUHK Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).
Hong Kong will be our springboard to the rest of APAC as we prepare for further developments in the region in due course and continue to set CMR Surgical on the global stage.
Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council commented: Hong Kong is a leader in embracing innovation and technology, including in Healthcare.
It is great to see Versius standing out in Hong Kong and offering world leading surgeons a very different surgical robotic option.

Hong Kong to be gateway for CMR Surgical in APAC region

Retrieved on:

Thursday, April 28, 2022

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at Chinese University of Hong Kong Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).

Key Points:

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at Chinese University of Hong Kong Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).
Hong Kong will be our springboard to the rest of Asia as we prepare for further developments in the APAC region in due course and continue to set CMR Surgical on the global stage.
Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council commented: Hong Kong is a leader in embracing innovation and technology, including in Healthcare.
We are delighted to be partnering with leading hospitals, Chinese University of Hong Kong Medical Centre and Gleneagles Hospital Hong Kong, to expand the benefits of robotic keyhole surgery.

GHK Capital Partners Raises $410 Million for Oversubscribed Inaugural Fund

Retrieved on:

Thursday, March 24, 2022

GHK Capital Partners LP (GHK), a leading middle-market private equity firm, has announced the final closing of GHK Fund I (the Fund).

Key Points:

GHK Capital Partners LP (GHK), a leading middle-market private equity firm, has announced the final closing of GHK Fund I (the Fund).
GHK accepted $410 million in aggregate capital commitments, exceeding its initial target of $350 million and surpassing its hard cap of $400 million.
This is the first private equity fund raised by GHK, which targets control investments in performing middle-market industrial companies across North America.
We are grateful and humbled by the investor support for our inaugural fund, commented Gil Klemann, Managing Partner.